SLC5A2 and diabetic cardiomyopathy: Therefore, future studies are necessary to further elucidate whether modulating myocardial ketone body oxidation can meaningfully impact the pathology of diabetic cardiomyopathy, and whether this may represent a potential cardioprotective mechanism of SGLT2 inhibitors.